Literature DB >> 12165467

Transgenic mouse model of tauopathies with glial pathology and nervous system degeneration.

Makoto Higuchi1, Takeshi Ishihara, Bin Zhang, Ming Hong, Athena Andreadis, John Trojanowski, Virginia M-Y Lee.   

Abstract

Frontotemporal dementias (FTDs), including corticobasal degeneration (CBD) and progressive supranuclear palsy (PSP), are neurodegenerative tauopathies characterized by widespread CNS neuronal and glial tau pathologies, but there are no tau transgenic (Tg) mice that model neurodegeneration with glia tau lesions. Thus, we generated Tg mice overexpressing human tau in neurons and glia. No neuronal tau aggregates were detected, but old mice developed Thioflavin S- and Gallyas-positive glial tau pathology resembling CBD astrocytic plaques. Tau-immunoreactive and Gallyas-positive oligodendroglial coiled bodies (similar to CBD and PSP), glial degeneration, and motor deficits were associated with age-dependent accumulations of insoluble hyperphosphorylated human tau and tau immunopositive filaments in degenerating glial cells. Thus, tau-positive glial lesions similar to human FTDs occur in these Tg mice, and these pathologies are linked to glial and axonal degeneration.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12165467     DOI: 10.1016/s0896-6273(02)00789-4

Source DB:  PubMed          Journal:  Neuron        ISSN: 0896-6273            Impact factor:   17.173


  42 in total

1.  Neurodegenerative tauopathy in the worm.

Authors:  Michel Goedert
Journal:  Proc Natl Acad Sci U S A       Date:  2003-08-11       Impact factor: 11.205

2.  Tau protein expression in adult bovine oligodendrocytes: functional and pathological significance.

Authors:  Hanna Ksiezak-Reding; Muhammad Farooq; Liang-sheng Yang; Dennis W Dickson; Patrizia LoPresti
Journal:  Neurochem Res       Date:  2003-09       Impact factor: 3.996

Review 3.  Tau-targeted treatment strategies in Alzheimer's disease.

Authors:  Jürgen Götz; Arne Ittner; Lars M Ittner
Journal:  Br J Pharmacol       Date:  2012-03       Impact factor: 8.739

4.  Wild type and P301L mutant Tau promote neuro-inflammation and α-Synuclein accumulation in lentiviral gene delivery models.

Authors:  Preeti J Khandelwal; Sonya B Dumanis; Alexander M Herman; G William Rebeck; Charbel E-H Moussa
Journal:  Mol Cell Neurosci       Date:  2011-09-14       Impact factor: 4.314

5.  Accelerated human mutant tau aggregation by knocking out murine tau in a transgenic mouse model.

Authors:  Kunie Ando; Karelle Leroy; Céline Héraud; Zehra Yilmaz; Michèle Authelet; Valèrie Suain; Robert De Decker; Jean-Pierre Brion
Journal:  Am J Pathol       Date:  2011-02       Impact factor: 4.307

Review 6.  The cytoskeleton in oligodendrocytes. Microtubule dynamics in health and disease.

Authors:  Christiane Richter-Landsberg
Journal:  J Mol Neurosci       Date:  2007-12-04       Impact factor: 3.444

Review 7.  Knock-out and transgenic mouse models of tauopathies.

Authors:  Franziska Denk; Richard Wade-Martins
Journal:  Neurobiol Aging       Date:  2007-06-22       Impact factor: 4.673

8.  Novel human neuronal tau model exhibiting neurofibrillary tangles and transcellular propagation.

Authors:  Patrick Reilly; Charisse N Winston; Kelsey R Baron; Margarita Trejo; Edward M Rockenstein; Johnny C Akers; Najla Kfoury; Marc Diamond; Eliezer Masliah; Robert A Rissman; Shauna H Yuan
Journal:  Neurobiol Dis       Date:  2017-06-10       Impact factor: 5.996

9.  Tau as a biomarker of neurodegenerative diseases.

Authors:  Susanna Schraen-Maschke; Nicolas Sergeant; Claire-Marie Dhaenens; Stéphanie Bombois; Vincent Deramecourt; Marie-Laure Caillet-Boudin; Florence Pasquier; Claude-Alain Maurage; Bernard Sablonnière; Eugeen Vanmechelen; Luc Buée
Journal:  Biomark Med       Date:  2008-08       Impact factor: 2.851

Review 10.  Protein astrogliopathies in human neurodegenerative diseases and aging.

Authors:  Gabor G Kovacs; Virginia M Lee; John Q Trojanowski
Journal:  Brain Pathol       Date:  2017-09       Impact factor: 6.508

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.